Global Cardio Oncology Registry

Description

G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.

Conditions

Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis, Cardiotoxicity, Cardiovascular Diseases

Study Overview

Study Details

Study overview

G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.

Global Cardio Oncology Registry

Global Cardio Oncology Registry

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Weston

Cleveland Clinic Florida, Weston, Florida, United States, 33331

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * New cardio-oncology consultation for breast cancer patients, or
  • * New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or
  • * New cardio-oncology consultation for acute or chronic leukemia patients, or
  • * New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or
  • * New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation.
  • * All patients have to be 18 years old or older
  • * Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators.
  • * Minors less than 18 years old.
  • * Inability or unwillingness to consent to participate

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The Cleveland Clinic,

Diego Sadler, MD FACC, PRINCIPAL_INVESTIGATOR, The Cleveland Clinic

Study Record Dates

2027-07-01